Cephalon's lestaurtinib misses AML endpoint

Cephalon Inc. (NASDAQ:CEPH) said top-line data showed lestaurtinib plus chemotherapy missed the primary endpoint of improving complete remission rate vs. chemotherapy alone in a pivotal Phase II trial...